What the company does
Aptn is developing a new drug aimed at treating Parkinson's disease, a progressive neurological condition caused by the loss of dopamine-producing brain cells.
The intended users are Parkinson's patients, particularly older adults for whom existing standard therapies offer only symptom relief and carry significant long-term side effects. Listed on KOSDAQ, Korea's tech and small-cap board, the company is expanding into the brain-disease treatment field by acquiring foundational technology rights and establishing a dedicated neurological-drug division.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$14.8M
- FY2024US$13.3M
- FY2025US$12.2M
Operating profit
- FY2023−US$4.7M
- FY2024−US$9.2M
- FY2025−US$8.1M
Net income
- FY2023−US$3.6M
- FY2024−US$13.9M
- FY2025−US$17M
Key ratios (FY2025)
Why it matters · Context, not a recommendation
Aptn acquired its core Parkinson's disease technology rights from Seoul National University's industry-academic cooperation foundation, which is the stated origin of its drug-development programme.
Filings
All disclosures · English when translatedPrice charts coming soon
Interactive price history isn't here yet. Would you use it?